Noveris Health Sciences Inc (FRA:0NF1) Stock Price, Trades & News

Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).

Financial Strength

4/10

Name	Current	Vs Industry
Cash-To-Debt	4.8
Equity-to-Asset	-1.1
Debt-to-Equity	-0.19
Debt-to-EBITDA	0.23
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year EPS without NRI Growth Rate	80.6
	3-Year Book Growth Rate	-32.9

Momentum Rank

2/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	61.88
	9-Day RSI	51.84
	14-Day RSI	49.11
	3-1 Month Momentum %	14.53
	6-1 Month Momentum %	1107.21
	12-1 Month Momentum %	2580

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.48
	Quick Ratio	0.48
	Cash Ratio	0.47

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-60.6
	Shareholder Yield %	-1.64

Profitability Rank

1/10

	Name	Current	Vs Industry		Vs History
	ROE %	Neg. Equity
	ROA %	302.45
	ROIC %	-7.6
	3-Year ROIIC %	178.71
	Years of Profitability over Past 10-Year	1
	Moat Score	3
	Tariff Resilience Score	6

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	0.84
	Price-to-Owner-Earnings	14.18
	EV-to-EBIT	54.86
	EV-to-EBITDA	54.86
	EV-to-Forward-Revenue	0.81
	EV-to-FCF	-350.98
	Earnings Yield (Greenblatt) %	1.82
	FCF Yield %	-0.28

Financials

Annual Quarterly TTM

FRA:0NF1's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Noveris Health Sciences Inc Executives

Details

GF Value™

FRA:0NF1

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected issues with 0NF1. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)
	EPS (TTM) (€)	1.26
	Beta	-38.1146
	3-Year Sharpe Ratio	0.82
	3-Year Sortino Ratio	9.69
	Volatility %	1709.64
	14-Day RSI	49.11
	14-Day ATR (€)	0.099951
	20-Day SMA (€)	0.9745
	12-1 Month Momentum %	2580
	52-Week Range (€)	0.05 - 1.81
	Shares Outstanding (Mil)	58.55

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	4
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Noveris Health Sciences Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Noveris Health Sciences Inc Stock Events

Financials Calendars

Event	Date	Price (€)
0.02:1 Stock Split	2025-10-21	0.05 (+0.00%)
0.02:1 Stock Split	2022-04-21	64.50 (+138.89%)
0.022222:1 Stock Split	2019-04-01	2,700.03 (+0.00%)

Show

Entries

Noveris Health Sciences Inc Frequently Asked Questions

What is Noveris Health Sciences Inc(FRA:0NF1)'s stock price today?

The current price of FRA:0NF1 is €1.01. The 52 week high of FRA:0NF1 is €1.81 and 52 week low is €0.05.

When is next earnings date of Noveris Health Sciences Inc(FRA:0NF1)?

The next earnings date of Noveris Health Sciences Inc(FRA:0NF1) is .

Does Noveris Health Sciences Inc(FRA:0NF1) pay dividends? If so, how much?

Noveris Health Sciences Inc(FRA:0NF1) does not pay dividend.

Press Release

	Subject	Date
	Mydecine to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th	2021-10-06
	Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option	2021-02-12
	Mydecine Innovations Group Files Final Prospectus in Connection with Bought Deal Offering of Units	2021-02-09
	Mydecine Innovations Group Files Amended and Restated Financial Statements	2021-02-05
	Mydecine Announces Change of Auditor	2021-01-21
	Mydecine Innovations Group Files Preliminary Prospectus in Connection with Bought Deal Offering of Units	2021-01-21
	KILL Mydecine Innovations Group Upsizes Previously Announced Bought Deal	2021-01-20
	KILL Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units	2021-01-20
	Mydecine Innovations Group Upsizes Previously Announced Bought Deal	2021-01-20
	Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units	2021-01-20

10/Page

Articles on Noveris Health Sciences Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.